{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:46:36Z","timestamp":1786992396387,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jgo.2025.102829","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:00:35Z","timestamp":1765836035000},"page":"102829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tolerability of immune checkpoint inhibitors for cancer treatment in frail, older patients"],"prefix":"10.1016","volume":"17","author":[{"given":"Rochelle","family":"Sheppard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Anstey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Hanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Ladwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jgo.2025.102829_bb0005","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jgo.2025.102829_bb0010","series-title":"Cancer data in Australia, an overview of cancer in Australia, 2024 [internet]","author":"Australian Institute of Health and Welfare","year":"2024"},{"issue":"1","key":"10.1016\/j.jgo.2025.102829_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","article-title":"The frailty syndrome: definition and natural history","volume":"27","author":"Xue","year":"2011","journal-title":"Clin Geriatr Med"},{"issue":"9","key":"10.1016\/j.jgo.2025.102829_bb0020","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/gerona\/63.9.984","article-title":"Initial manifestations of frailty criteria and the development of frailty phenotype in the women\u2019s health and aging study II","volume":"63","author":"Xue","year":"2008","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"10.1016\/j.jgo.2025.102829_bb0025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1532-5415.2009.02137.x","article-title":"Osteoporotic fractures in men research group. A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men","volume":"57","author":"Ensrud","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.jgo.2025.102829_bb0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.14283\/jfa.2022.44","article-title":"Predictive abilities of the frailty phenotype and the Swiss frailty network and repository frailty index for non-home discharge and functional decline in hospitalized geriatric patients","volume":"11","author":"Stuck","year":"2022","journal-title":"J Frailty Aging"},{"issue":"6","key":"10.1016\/j.jgo.2025.102829_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afae125","article-title":"Development and validation of a frailty index for use in the osteoarthritis initiative","volume":"53","author":"O\u2019Brien","year":"2024","journal-title":"Age Ageing"},{"key":"10.1016\/j.jgo.2025.102829_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2016.03.007","article-title":"Frailty measurement in research and clinical practice: a review","volume":"31","author":"Dent","year":"2016","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jgo.2025.102829_bb0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/CIA.S365494","article-title":"Frailty and cancer: current perspectives on assessment and monitoring","volume":"18","author":"Goede","year":"2023","journal-title":"Clin Interv Aging"},{"issue":"3","key":"10.1016\/j.jgo.2025.102829_bb0050","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.jgo.2025.102829_bb0055","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","article-title":"The prevalence and outcomes of frailty in older cancer patients: a systematic review","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2025.102829_bb0060","first-page":"362","article-title":"Frailty, and cancer: implications for oncology surgery, medical oncology, and radiation oncology","volume":"67","author":"Ethun","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.jgo.2025.102829_bb0065","first-page":"8","article-title":"Frailty in older adults: assessment, support, and treatment implications in patients with cancer","volume":"22","author":"Overcash","year":"2018","journal-title":"Clin J Oncol Nurs"},{"issue":"4","key":"10.1016\/j.jgo.2025.102829_bb0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.14283\/jfa.2024.22","article-title":"Frailty index, not age, predicts treatment outcomes and adverse events for older adults with cancer","volume":"13","author":"Fletcher","year":"2024","journal-title":"J Frailty Aging"},{"issue":"1","key":"10.1016\/j.jgo.2025.102829_bb0075","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1186\/s12885-018-4807-6","article-title":"Validation of a frailty index in older cancer patients with solid tumours","volume":"18","author":"McCarthy","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2025.102829_bb0080","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2025.102829_bb0085","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3389\/fphar.2019.01260","article-title":"The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non-small cell lung cancer and melanoma: network meta-analysis and systematic review","volume":"10","author":"Chai","year":"2019","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jgo.2025.102829_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100577","article-title":"The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression","volume":"7","author":"Kim","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.jgo.2025.102829_bb0095","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1111\/ajag.12231","article-title":"Feasibility and construct validity of a frailty index for patients with chronic kidney disease","volume":"34","author":"Hubbard","year":"2015","journal-title":"Australas J Ageing"},{"issue":"1","key":"10.1016\/j.jgo.2025.102829_bb0100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1186\/s12877-021-02671-3","article-title":"How frail is frail? A systematic scoping review and synthesis of high impact studies","volume":"21","author":"Gordon","year":"2021","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jgo.2025.102829_bb0105","series-title":"StatPearls [Internet]","article-title":"Clinical frailty scale. 2023 Apr 23","author":"Mendiratta","year":"2024"},{"key":"10.1016\/j.jgo.2025.102829_bb0110","series-title":"StatPearls [Internet]","article-title":"TNM classification. 2023 Feb 13","author":"Rosen","year":"2024"},{"key":"10.1016\/j.jgo.2025.102829_bb0115","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-016-2408-9","article-title":"Use, and misuse of common terminology criteria for adverse events in cancer clinical trials","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2025.102829_bb0120","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/biom.12916","article-title":"A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect","volume":"74","author":"Ye","year":"2018","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.jgo.2025.102829_bb0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/biology12020191","article-title":"Impact of frailty on outcomes of first-line Pembrolizumab monotherapy in a real-world population with advanced non-small cell lung cancer","volume":"12","author":"Jim\u00e9nez Gal\u00e1n","year":"2023","journal-title":"Biol-Basel"},{"issue":"2","key":"10.1016\/j.jgo.2025.102829_bb0130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"issue":"15_suppl","key":"10.1016\/j.jgo.2025.102829_bb0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.10010","article-title":"FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers","volume":"34","author":"Singh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2025.102829_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2025.102829_bb0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-9966-33-30","article-title":"Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme","volume":"33","author":"Chiarion Sileni","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jgo.2025.102829_bb0150","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cancers16112159","article-title":"Real-world prevalence and tolerability of immune-related adverse events in older adults with non-small cell lung cancer: a multi-institutional retrospective study","volume":"16","author":"Matsukane","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jgo.2025.102829_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.jgo.2025.102829_bb0160","doi-asserted-by":"crossref","first-page":"13217","DOI":"10.1002\/cam4.6013","article-title":"Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: a retrospective cohort study","volume":"12","author":"Olsson Ladjevardi","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.jgo.2025.102829_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101742","article-title":"Immunotherapy use in older adults with cancer with frailty: a young SIOG review paper","volume":"15","author":"Guven","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2025.102829_bb0170","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/cncr.34230","article-title":"Frailty and checkpoint inhibitor toxicity in older patients with melanoma","volume":"128","author":"Bruijnen","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2025.102829_bb0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2018.08.006","article-title":"Aging, immune senescence, and immunotherapy: a comprehensive review","volume":"45","author":"Elias","year":"2018","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2025.102829_bb0180","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/oncolo\/oyac119","article-title":"Immune checkpoint inhibitors: the unexplored landscape of geriatric oncology","volume":"27","author":"Choucair","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2025.102829_bb0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2017.05.044","article-title":"Immune checkpoint inhibitors and elderly people: a review","volume":"82","author":"Daste","year":"2017","journal-title":"Eur J Cancer"},{"issue":"20","key":"10.1016\/j.jgo.2025.102829_bb0190","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.21037\/atm-22-4405","article-title":"Immunosenescence is a therapeutic target for frailty in older adults: a narrative review","volume":"10","author":"Jia","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jgo.2025.102829_bb0195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381134","article-title":"Frailty, inflammation and Immunosenescence","volume":"41","author":"Fulop","year":"2015","journal-title":"Interdiscip Top Gerontol Geriatr"},{"issue":"10","key":"10.1016\/j.jgo.2025.102829_bb0200","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40266-019-00697-2","article-title":"Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer","volume":"36","author":"van Holstein","year":"2019","journal-title":"Drugs Aging"},{"issue":"Suppl. 9","key":"10.1016\/j.jgo.2025.102829_bb0205","article-title":"1128P - the European Ipilimumab expanded access programme (EAP): efficacy and safety data from the Italian cohort of patients with pretreated, advanced melanoma","volume":"23","author":"Ascierto","year":"2012","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2025.102829_bb0210","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jgo.2025.102829_bb0215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2021.06.004","article-title":"Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score \u22652 - systematic review and meta-analysis","volume":"158","author":"Tomasik","year":"2021","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2025.102829_bb0220","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/cancers16040709","article-title":"Reasons for treatment discontinuation and their effect on outcomes of immunotherapy in Southwest Finland: a retrospective, real-world cohort study","volume":"16","author":"Virtanen","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.jgo.2025.102829_bb0225","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/cancers13112826","article-title":"Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors","volume":"13","author":"de Glas","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jgo.2025.102829_bb0230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40266-024-01114-z","article-title":"Toxicity in older patients with cancer receiving immunotherapy: an observational study","volume":"41","author":"Tran Van Hoi","year":"2024","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.jgo.2025.102829_bb0235","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/picr.PICR_87_17","article-title":"Common pitfalls in statistical analysis: logistic regression","volume":"8","author":"Ranganathan","year":"2017","journal-title":"Perspect Clin Res"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825006459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406825006459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:35:16Z","timestamp":1774056916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406825006459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1879406825006459"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102829","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability of immune checkpoint inhibitors for cancer treatment in frail, older patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2025.102829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102829"}}